UNCY - NASDAQ

Unicycive Therapeutics, Inc.

UNCY·NASDAQ

$7.50

+4.7%

HealthcareBiotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$161.19M

EPS-1.6700

P/E Ratio-4.49

Earnings Date08/13/2026

49.13M

Assets

55%

3Y+1644.0%

5Y+23986.0%

10Y+169331.0%

18.94M

Total Liabilities

-22%

3Y+477.0%

5Y+559.0%

10Y+1433.0%

30.20M

Total Equity

306%

3Y-6580.0%

5Y-1231.0%

10Y-2604.0%

Unicycive Therapeutics, Inc. Funding & Solvency Profile

UNCY · NASDAQ

Current Assets

Cash & Cash Equivalents29.20M

Net Receivables0.00

Inventory0.00

Other Current Assets7.69M

Total Current Assets49 M

Non-Current Assets

Property, Plant & Equipment174.00K

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets0.00

Total Non-Current Assets174 K

Total Assets

49.13M

Financial Health Analysis

Current Ratio

2.59x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.63x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

30 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

100% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Unicycive Therapeutics, Inc. Balance Sheet

UNCY • NASDAQ

Unicycive Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	29.2M	26.1M	9.7M	455K	16.6M	0.0	15K	25K
Short-Term Investments	12.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	41.3M	26.1M	9.7M	455K	16.6M	0.0	15K	25K
Prepaids	0.0	3.9M	3.4M	2M	1.7M	0.0	0.0	4K
Other Current Assets	7.7M	939K	325K	159K	126K	204K	4K	0.0
Total Current Assets	49M	30.9M	13.4M	2.6M	18.4M	204K	19K	29K
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	174K	720K	792K	174K	333K	0.0	0.0	0.0
Other Non-Current Assets	0.0	0.0	0.0	0.0	0.0	200K	0.0	0.0
Total Non-Current Assets	174K	720K	792K	174K	333K	200K	0.0	0.0
Other Assets	0.0	0.0	0.0	0.0	0.0	-200K	0.0	0.0
Total Assets	49.1M	31.7M	14.2M	2.8M	18.7M	204K	19K	29K
LIABILITIES
CURRENT LIABILITIES
Total Payables	383K	966K	821K	846K	742K	184K	322K	60K
Accounts Payable	383K	966K	821K	846K	742K	184K	322K	60K
Accrued Expenses	0.0	3.6M	3.2M	2.2M	1.2M	177K	121K	128K
Short Term Debt	117K	92K	18K	46K	29K	2.5M	460K	1M
Capital Lease Obligations (Current)	0.0	564K	327K	155K	151K	0.0	0.0	0.0
Other Current Liabilities	18.4M	18.9M	13.1M	0.0	-29K	0.0	0.0	0.0
Total Current Liabilities	18.9M	24.1M	17.5M	3.3M	2.1M	2.9M	903K	1.2M
NON-CURRENT LIABILITIES
Total Non-Current Liabilities	0.0	117K	466K	0.0	155K	0.0	0.0	0.0
Capital Lease Obligations	0.0	681K	793K	155K	306K	0.0	0.0	0.0
Total Liabilities	18.9M	24.2M	18M	3.3M	2.3M	2.9M	903K	1.2M
SHAREHOLDERS' EQUITY
Common Stock	22K	114K	35K	15K	15K	9K	8K	34K
Additional Paid-In Capital	0.0	108.6M	60.7M	33.5M	32.4M	3.2M	2.8M	253K
Retained Earnings	-127.8M	-101.3M	-64.5M	-34M	-15.9M	-5.9M	-3.7M	-1.5M
Accumulated Other Comprehensive Income/Loss	-1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Total Stockholders' Equity	158M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Stockholders' Equity	30.2M	7.4M	-3.8M	-466K	16.5M	-2.7M	-884K	-1.2M
Total Equity	30.2M	7.4M	-3.8M	-466K	16.5M	-2.7M	-884K	-1.2M
SUMMARY
Total Liabilities & Equity	49.1M	31.7M	14.2M	2.8M	18.7M	204K	19K	29K
Total Investments	12.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Debt	117K	773K	811K	201K	335K	2.5M	460K	1M
Net Debt	-29.1M	-25.4M	-8.9M	-254K	-16.2M	2.5M	445K	1M
Shares Outstanding	17,661,698	17,661,698	17,661,698	17,661,698	17,661,698	17,661,698	17,661,698	17,661,698

SEC Filings

UNCY - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 12, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 12, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 30, 2026	June 19, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 06, 2026	April 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 30, 2026	March 30, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 30, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 14, 2025	November 14, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing
8-K 8-K 2025 N/A	October 28, 2025	October 28, 2025	2025	View Filing

Showing 1 to 10 of 100 filings

Related Guides

Blog Categories

Continue your UNCY research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.